Psychiatry Advisor3d
Long-Term Gantenerumab May Slow Decline in Dominantly Inherited Alzheimer Disease
For individuals with dominantly inherited Alzheimer disease (DIAD), long-term treatment with gantenerumab may delay clinical decline.
Early-onset Alzheimer’s: Drug shows promise in slowing the disease
Early-onset Alzheimer’s disease progresses more rapidly and often strikes people in the prime of their lives. A new treatment ...
pharmaphorum14h
Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug
Buoyed by new results from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's ...
WashU could be paving path for delaying onset Alzheimer’s symptoms
Researchers at Washington University in St. Louis are making potential findings in delaying the onset of Alzheimer’s symptoms ...
pharmaphorum3d
Gantenerumab 'shows sign of preventing Alzheimer's dementia'
Randall Bateman, MD, Charles F and Joanne Knight Distinguished Professor of Neurology at WashU Medicine. A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to ...
ophthalmologyadvisor6d
Long-Term Gantenerumab May Slow Decline in Dominantly Inherited Alzheimer Disease
The hazard ratio for clinical decline in Clinical Dementia Rating-Sum of Boxes was 0.53 for those treated with gantenerumab the longest. HealthDay News — For individuals with dominantly inherited ...
BMJ3d
How effective is effective enough?
AB serves on scientific advisory boards for Eisai (lecanemab), Biogen (aducanumab) and Roche (gantenerumab), as was a PI for the TRAILBLAZER (Lilly) and ENGAGE (Biogen) studies.